Management of chronic hepatitis B in children: An unresolved issue

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 5, 2014, Pages 912-919

  Della Corte, Claudia ^a   Nobili, Valerio ^a   Comparcola, Donatella ^a   Cainelli, Francesca ^b   Vento, Sandro ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF BOTSWANA   (Botswana)

Author keywords

Antiviral therapy; Children; HBV infection

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; GUANINE; INTERFERON; NUCLEOSIDE; PHOSPHONIC ACID DERIVATIVE;

CANCER RISK; CHILDHOOD DISEASE; CHRONIC HEPATITIS; DEVELOPING COUNTRY; EMBASE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL LITERATURE; MEDLINE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; BIBLIOGRAPHIC DATABASE; CARCINOMA, HEPATOCELLULAR; CHILD; COMPLICATION; HEPATITIS B, CHRONIC; HETEROZYGOTE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INCIDENCE; LIVER NEOPLASMS; META ANALYSIS; RISK;

ADENINE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; CHILD; DATABASES, BIBLIOGRAPHIC; GUANINE; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; INCIDENCE; INTERFERONS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; NUCLEOSIDES; ORGANOPHOSPHONATES; RISK;

EID: 84898897207     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12550     Document Type: Review

References (73)

1. World Health Organization. Media Centre. Hepatitis B [Internet]. Cited 2 Jan 2013. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html
2. Lavanchy D. Hepatitis B. Virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
3. World Health Organization. Global routine vaccination coverage, 2011. Wkly. Epidemiol. Rec. 2012; 87: 432-435.
4. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int. J. Infect. Dis. 2012; 16: e82-88.
5. Liang X, Bi S, Yang W etal. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-6557.
6. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J. Hepatol. 2012; 57: 730-735.
7. Chen SM, Kung CM, Yang WJ, Wang HL. Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. J. Clin. Virol. 2011; 52: 11-16.
8. Romano L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig. Liver Dis. 2011; 43 (Suppl. 1): S2-7.
9. Sorrell MF, Belongia EA, Costa J etal. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 2009; 150: 104-110.
10. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J. Clin. Virol. 2005; 34 (Suppl. 1): S1-3.
11. Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J. Gastroenterol. 2011; 46: 1-8.
12. Chen X, Chen J, Wen J etal. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. PLoS ONE 2013; 8: e55303. doi: 10.1371/journal.pone.0055303
13. Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J. Pediatr. Gastroenterol. Nutr. 1993; 16: 66-69.
14. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow up study. J. Pediatr. 1998; 133: 374-377.
15. World Health Organization. Hepatitis B vaccines. Wkly. Epidemiol. Rec. 2009; 84: 405-420. Cited 2 Jan 2013. Available from URL: http://www.who.int/wer
16. Su FH, Chu FY, Bai CH etal. Efficacy of hepatitis B vaccine boosters among neonatally vaccinated university freshmen in Taiwan. J. Hepatol. 2013; 58: 684-689.
17. Elisofon SA, Jonas MM. Hepatitis B and C in children: current treatment and future strategies. Clin. Liver Dis. 2006; 10: 133-148.
18. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38: 1075-1086.
19. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J. Med. Virol. 1986; 18: 301-307.
20. Bortolotti F, Cadrobbi P, Crivellaro C, Bertaggia A, Realdi G, Alberti A. Chronic hepatitis type B in childhood: longitudinal study of 35 cases. Gut 1981; 22: 499-504.
21. Bortolotti F, Cadrobbi P, Crivellaro C etal. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B infection in childhood. Gastroenterology 1990; 99: 805-810.
22. Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J. Clin. Microbiol. 2002; 40: 16-21.
23. Chen M, Sällberg M, Hughes J etal. Immune tolerance split between hepatitis B virus pre-core and core proteins. J. Virol. 2005; 79: 3016-3027.
24. Ni YH, Chang MH, Chen PJ etal. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007; 132: 2340-2345.
25. Iorio R, Giannattasio A, Cirillo F, D'Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin. Infect. Dis. 2007; 45: 943-949.
26. Bortolotti F, Guido M, Bartolacci S etal. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-562.
27. Fujisawa T, Komatsu H, Inui A etal. Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 201-206.
28. Manzat Saplacan RM, Mircea PA, Valean SD etal. The long-term evolution of chronic hepatitis B acquired in childhood. J. Gastrointestin. Liver Dis. 2009; 18: 433-438.
29. Boxall EH, Sira J, Standish RA etal. Natural history of hepatitis B in perinatally infected carriers. Arch. Dis. Child. Fetal Neonatal Ed. 2004; 89: F456-460.
30. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J. Infect. Dis. 2002; 186: 295-301.
31. Wen W-H, Chang M-H, Hsu H-Y, Ni Y-H, Chen H-L. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J. Pediatr. 2004; 144: 397-399.
32. Keefee EB, Dieterich DT, Han SH etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 2008; 6: 1315-1341.
33. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-242.
34. Lok AS, McMahon BJ. Chronic hepatitis B (AASLD practice guidelines). Hepatology 2001; 34: 1225-1241.
35. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. AASLD practice guideline. Hepatology 2009; 50: 661-662.
36. Shah U, Kelly D, Chang M-H etal. Management of chronic hepatitis B in children. J. Pediatr. Gastroenterol. Nutr. 2009; 48: 399-404.
37. Jonas MM, Block JM, Haber BA etal. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010; 52: 2192-2205.
38. Sokal EM, Paganelli M, Wirth S etal. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J. Hepatol. 2013; 59: 814-829.
39. Shneider BL, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: hepatitis B, C and NAFLD: summary of a single topic conference. Hepatology 2006; 44: 1344-1354.
40. Kerkar N. Hepatitis B in children: complexities in management. Pediatr. Transplant. 2005; 9: 685-691.
41. Haber BA, Block JM, Jonas MM etal. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009; 124: e1007-1013.
42. Paganelli M, Stephenne X, Sokal E. Chronic hepatitis B in children and adolescents. J. Hepatol. 2012; 57: 885-896.
43. Scaglione SJ, Lok ASF. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012; 142: 1360-1368.
44. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
45. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol. Int. 2008; 2: S28-36.
46. Sokal EM, Conjeevaram HS, Roberts EA etal. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995.
47. Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B. Pediatr. Infect. Dis. J. 2004; 23: 441-445.
48. Murray KF, Szenborn L, Wysocki J etal. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-2026.
49. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin. Liver Dis. 2004; 24 (Suppl. 1): 45-53.
50. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J. Pediatr. 1995; 127: 815-818.
51. Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J. Pediatr. 2004; 145: 340-345.
52. Bortolotti F, Jara P, Barbera C etal. Long-term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-718.
53. Vo Thi Diem H, Bourgois A, Bontems P etal. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J. Pediatr. Gastroenterol. Nutr. 2005; 40: 141-145.
54. Cooksley WG, Piratvisuth T, Lee SD etal. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 2003; 10: 298-305.
55. Jonas MM, Kelley DA, Mizerski J etal. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 2002; 346: 1706-1713.
56. Hagmann S, Chung M, Rochford G etal. Response to lamivudine in children with chronic hepatitis B virus infection. Clin. Infect. Dis. 2003; 37: 1434-1440.
57. Hartman C, Berkowitz D, Shouval D etal. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr. Infect. Dis. J. 2003; 22: 224-228.
58. Jonas MM, Kelly D, Pollack H etal. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863-1871.
59. Jonas MM, Kelly D, Pollack H etal. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr. Infect. Dis. J. 2012; 31: 578-582.
60. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
61. Sherman M, Yurdaydin C, Simsek H etal. Entecavir therapy for lamivudine refractory chronic hepatitis B: improved virologic, biochemical and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108.
62. Bristol-Myers Squibb. A phase III study of the safety and efficacy of entecavir in pediatric patients with chronic HBV infection. In: ClinicalTrials.gov. NCT01079806. Cited 21 Feb 2013. Available from URL: http://clinicaltrials.gov/show/NCT01079806
63. Schwarz K. Clinical trial of entecavir/pegylated interferon in immune tolerant children with chronic HBV infection (HBRN). In: ClinicalTrials.gov. NCT01368497. Cited 21 Feb 2013. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT01368497
64. Woo G, Tomlinson G, Nishikawa Y etal. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta analyses. Gastroenterology 2010; 139: 1218-1229.
65. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-2455.
66. Emre S, Umman V, Cimsit B, Rosencrantz R. Current concepts in pediatric liver transplantation. Mt. Sinai J. Med. 2012; 79: 199-213.
67. Tiao GM, Alonso MH, Ryckman FC. Pediatric liver transplantation. Semin. Pediatr. Surg. 2006; 15: 218-222.
68. Burra P, Germani G, Adam R etal. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J. Hepatol. 2013; 58: 287-296.
69. Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin. Liver Dis. 2011; 15: 753-764.
70. Jiang L, Jiang L, Cheng N etal. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J. Gastroenterol. 2009; 15: 2489-2499.
71. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004; 10: 968-974.
72. Thomas H. Treatment of chronic hepatitis B in resource-constrained countries: an economic solution is required. J. Viral Hepat. 2013; 20 (Suppl. 1): 2. doi: 10.1111/jvh.12057
73. Shamliyan TA, Johnson JR, MacDonald R etal. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J. Gen. Intern. Med. 2011; 26: 326-339.